Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012

Phase 0 Completed 10 enrolled Centre Jean Perrin

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is a phase I clinical trial aimed to determine the recommended dose of \[131I\]ICF01012 to administer for the treatment of patients with pigmented metastatic melanoma (binding \[131I\]ICF01012 ). The \[131I\]ICF01012 is a targeted radionuclide therapy with a high affinity for melanin.

Timeline

Start: 2019-10-18
Primary completion: 2025-01-17
Completion: 2025-01-17

Publications

Thivat E, Rouanet J, Auzeloux P, Sas N, Jouberton E, Levesque S, Billoux T, Mansard S, Molnar I, Chanchou M, Fois G, Maigne L, Chezal JM, Miot-Noirault E, D'Incan M, Durando X, Cachin F. Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. BMC Cancer. 2022 Apr 15;22(1):417. doi: 10.1186/s12885-022-09495-3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[131I]ICF01012	Other / unclassified	185 mbq	Intravenous
Subject	[131I]ICF01012	Other / unclassified	800 mbq	Intravenous
Subject	[131I]ICF01012	Other / unclassified	1600 mbq	Intravenous
Subject	[131I]ICF01012	Other / unclassified	2700 mbq	Intravenous
Subject	[131I]ICF01012	Other / unclassified	4000 mbq	Intravenous

Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012

Summary

Timeline

Publications

Drugs

Indications